logo
Plus   Neg
Share
Email

Alexion : Japan Okays Soliris For Prevention Of Relapse In Patients With NMOSD

Alexion Pharmaceuticals Inc. (ALXN) said that Japan's Ministry of Health, Labour and Welfare has approved the extension of the current marketing authorization of SOLIRIS (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder or NMOSD, including neuromyelitis optica.

NMOSD is a rare, devastating, complement-mediated disorder of the central nervous system characterized by relapses, also referred to as attacks. Each attack can result in stepwise accumulation of disability, including blindness and paralysis and sometimes premature death.

SOLIRIS was approved for the treatment of NMOSD in adult patients who are anti-AQP4 antibody-positive by the U.S. Food and Drug Administration (FDA) in June 2019 and by the European Commission in August 2019.

SOLIRIS received Orphan Drug Designation for the treatment of NMOSD in the U.S., EU and Japan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PG&E agreed to pay around $13.5 billion to settle all individual claims related to California wildfires, due to which the electric utility had to file for bankruptcy. With the Bankruptcy Court's approval of the settlement agreement, PG&E hopes to emerge from Chapter 11 by the June 30, 2020 deadline to participate in the State of California's go-forward wildfire fund. Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director...
Follow RTT
>